August 6, 2013
August 6, 2013 —
Neurosurgeons at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors.
November 20, 2018
November 20, 2018 —
A team of University of California San Diego School of Medicine researchers have been awarded a $1 million Stand Up To Cancer (SU2C) grant to test drugs that block signals that play a critical role in driving growth and progression of pancreatic cancer.
August 24, 2017
August 24, 2017 —
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved an $18.29 million grant to University of California San Diego School of Medicine researchers to fund a phase Ib/IIa clinical trial of a novel combination drug therapy for B-cell cancers.
April 29, 2015
April 29, 2015 —
…near complete remission in mouse models of advanced prostate cancer. The study is published April 29 in Nature.
June 28, 2023
June 28, 2023 —
UC San Diego researchers find a combination of drugs outperformed other treatments in human and mouse models of pancreatic cancer; now urge clinical trial
December 5, 2013
December 5, 2013 —
…antibiotics and developing new drugs against bacteria already resistant to conventional drug treatments. But understanding how bacteria grow and evolve drug resistance could also help stop its spread by allowing scientists to target the process of evolution itself. “Understanding how bacteria harboring antibiotic resistance grow in the presence of antibiotics…
June 21, 2012
June 21, 2012 —
…new pathway might be a fruitful target for new cancer drugs.
December 7, 2018
December 7, 2018 —
David Cheresh, Distinguished Professor at University of California San Diego School of Medicine, received $4.2 million National Cancer Institute Outstanding Investigator Award to continue his research into cancer’s ability to overcome stress, gain drug resistance and metastasize.
October 20, 2015
October 20, 2015 —
…most common types of cancer. This important drug has now been shown to play an unexpected role in blocking one of the pathways most commonly involved in driving the growth of cancers, according to a recent study by researchers at the San Diego Supercomputer Center (SDSC) as well as the…
September 25, 2012
September 25, 2012 —
Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.